Neuropathic Pain – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Neuropathic Pain – Pipeline Review, H2 2016’, provides an overview of the Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain

The report reviews pipeline therapeutics for Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Neuropathic Pain therapeutics and enlists all their major and minor projects

The report assesses Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Neuropathic Pain

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

2-BBB Medicines BV

AbbVie Inc

Acadia Pharmaceuticals Inc

Achelios Therapeutics Inc

Adynxx Inc

Aevi Genomic Medicine Inc

Affectis Pharmaceuticals AG

Amura Holdings Ltd

AnaBios Corp

Anavex Life Sciences Corp

AngioChem Inc

APT Therapeutics Inc

Aquilus Pharmaceuticals Inc

Araim Pharmaceuticals Inc

Arena Pharmaceuticals Inc

Asahi Kasei Pharma Corp

Astellas Pharma Inc

AstraZeneca Plc

BCI Pharma

Biogen Inc

BioLineRx Ltd

Biomar Microbial Technologies

Bionomics Ltd

Bristol-Myers Squibb Company

Can-Fite BioPharma Ltd

Cara Therapeutics Inc

Catalyst Biosciences Inc

Cavion LLC

Centrexion Therapeutics Corp

Cerecor Inc

Chromocell Corp

Circuit Therapeutics Inc

CLL Pharma SA

Colby Pharmaceutical Company

ContraVir Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Cytogel Pharma LLC

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Company Ltd

Develco Pharma Schweiz AG

Dompe Farmaceutici SpA

Eisai Co Ltd

Eli Lilly and Company

Endece LLC

Evec Inc

Genecode AS

Glenmark Pharmaceuticals Ltd

Glialogix Inc

Grunenthal GmbH

GW Pharmaceuticals Plc

Hydra Biosciences Inc

Immune Pharmaceuticals Inc

Inpellis Inc

Integral Molecular Inc

Intellipharmaceutics International Inc

iX Biopharma Ltd

Jeil Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Nhwa Pharmaceutical Corp Ltd

Johnson & Johnson

Kareus Therapeutics SA

Knopp Biosciences LLC

Kolon Life Science Inc

KPI Therapeutics Inc

Laboratorios Del Dr Esteve SA

Lexicon Pharmaceuticals Inc

Lohocla Research Corp

Lpath Inc

Mapi Pharma Ltd

Medestea Research & Production SpA

Medifron DBT Co Ltd

Medisyn Technologies Inc

Medy-Tox Inc

Merck & Co Inc

Nanomerics Ltd

Neurim Pharmaceuticals Ltd

Neurocentrx Pharma Ltd

NeuroCycle Therapeutics GmbH

NeuroMax

NeurOp Inc

Newron Pharmaceuticals SpA

Nippon Chemiphar Co Ltd

NoNO Inc

Novaremed Ltd

Novartis AG

NsGene A/S

Omeros Corp

Orion Oyj

Patagonia Pharmaceuticals LLC

PeriphaGen Inc

Pfizer Inc

Pharmaleads SA

PharmEste Srl

Phosphagenics Ltd

Prismic Pharmaceuticals Inc

RaQualia Pharma Inc

Re-Pharm Ltd

Relmada Therapeutics Inc

Revance Therapeutics Inc

Saniona AB

Scilex Pharmaceuticals Inc

Shionogi & Co Ltd

SK Biopharmaceuticals Co Ltd

Sphaera Pharma Pvt Ltd

Spherium Biomed SL

Sunovion Pharmaceuticals Inc

Syntrix Biosystems Inc

Takeda Pharmaceutical Company Ltd

Teva Pharmaceutical Industries Ltd

Theranexus SAS

Theravasc Inc

Toray Industries Inc

Torrent Pharmaceuticals Ltd

Trevena Inc

Trigemina Inc

Virobay Inc

VistaGen Therapeutics Inc

Vitality Biopharma Inc

Yuhan Corp

Yungjin Pharm Co Ltd

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Neuropathic Pain Overview 9

Therapeutics Development 10

Neuropathic Pain - Therapeutics under Development by Companies 12

Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 22

Neuropathic Pain - Pipeline Products Glance 24

Neuropathic Pain - Products under Development by Companies 28

Neuropathic Pain - Products under Investigation by Universities/Institutes 42

Neuropathic Pain - Companies Involved in Therapeutics Development 44

Neuropathic Pain - Therapeutics Assessment 165

Drug Profiles 188

Neuropathic Pain - Dormant Projects 491

Neuropathic Pain - Discontinued Products 516

Neuropathic Pain - Product Development Milestones 524

Appendix 534

List of Tables

List of Tables

Number of Products under Development for Neuropathic Pain, H2 2016 36

Number of Products under Development for Neuropathic Pain – Comparative Analysis, H2 2016 37

Number of Products under Development by Companies, H2 2016 38

Number of Products under Development by Companies, H2 2016 (Contd..1) 39

Number of Products under Development by Companies, H2 2016 (Contd..2) 40

Number of Products under Development by Companies, H2 2016 (Contd..3) 41

Number of Products under Development by Companies, H2 2016 (Contd..4) 42

Number of Products under Development by Companies, H2 2016 (Contd..5) 43

Number of Products under Development by Companies, H2 2016 (Contd..6) 44

Number of Products under Development by Companies, H2 2016 (Contd..7) 45

Number of Products under Development by Companies, H2 2016 (Contd..8) 46

Number of Products under Development by Companies, H2 2016 (Contd..9) 47

Number of Products under Investigation by Universities/Institutes, H2 2016 48

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 49

Comparative Analysis by Late Stage Development, H2 2016 50

Comparative Analysis by Clinical Stage Development, H2 2016 51

Comparative Analysis by Early Stage Development, H2 2016 52

Comparative Analysis by Unknown Stage Development, H2 2016 53

Products under Development by Companies, H2 2016 54

Products under Development by Companies, H2 2016 (Contd..1) 55

Products under Development by Companies, H2 2016 (Contd..2) 56

Products under Development by Companies, H2 2016 (Contd..3) 57

Products under Development by Companies, H2 2016 (Contd..4) 58

Products under Development by Companies, H2 2016 (Contd..5) 59

Products under Development by Companies, H2 2016 (Contd..6) 60

Products under Development by Companies, H2 2016 (Contd..7) 61

Products under Development by Companies, H2 2016 (Contd..8) 62

Products under Development by Companies, H2 2016 (Contd..9) 63

Products under Development by Companies, H2 2016 (Contd..10) 64

Products under Development by Companies, H2 2016 (Contd..11) 65

Products under Development by Companies, H2 2016 (Contd..12) 66

Products under Development by Companies, H2 2016 (Contd..13) 67

Products under Investigation by Universities/Institutes, H2 2016 68

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 69

Neuropathic Pain – Pipeline by 2-BBB Medicines BV, H2 2016 70

Neuropathic Pain – Pipeline by AbbVie Inc, H2 2016 71

Neuropathic Pain – Pipeline by Acadia Pharmaceuticals Inc, H2 2016 72

Neuropathic Pain – Pipeline by Achelios Therapeutics Inc, H2 2016 73

Neuropathic Pain – Pipeline by Adynxx Inc, H2 2016 74

Neuropathic Pain – Pipeline by Aevi Genomic Medicine Inc, H2 2016 75

Neuropathic Pain – Pipeline by Affectis Pharmaceuticals AG, H2 2016 76

Neuropathic Pain – Pipeline by Amura Holdings Ltd, H2 2016 77

Neuropathic Pain – Pipeline by AnaBios Corp, H2 2016 78

Neuropathic Pain – Pipeline by Anavex Life Sciences Corp, H2 2016 79

Neuropathic Pain – Pipeline by AngioChem Inc, H2 2016 80

Neuropathic Pain – Pipeline by APT Therapeutics Inc, H2 2016 81

Neuropathic Pain – Pipeline by Aquilus Pharmaceuticals Inc, H2 2016 82

Neuropathic Pain – Pipeline by Araim Pharmaceuticals Inc, H2 2016 83

Neuropathic Pain – Pipeline by Arena Pharmaceuticals Inc, H2 2016 84

Neuropathic Pain – Pipeline by Asahi Kasei Pharma Corp, H2 2016 85

Neuropathic Pain – Pipeline by Astellas Pharma Inc, H2 2016 86

Neuropathic Pain – Pipeline by AstraZeneca Plc, H2 2016 87

Neuropathic Pain – Pipeline by BCI Pharma, H2 2016 88

Neuropathic Pain – Pipeline by Biogen Inc, H2 2016 89

Neuropathic Pain – Pipeline by BioLineRx Ltd, H2 2016 90

Neuropathic Pain – Pipeline by Biomar Microbial Technologies, H2 2016 91

Neuropathic Pain – Pipeline by Bionomics Ltd, H2 2016 92

Neuropathic Pain – Pipeline by Bristol-Myers Squibb Company, H2 2016 93

Neuropathic Pain – Pipeline by Can-Fite BioPharma Ltd, H2 2016 94

Neuropathic Pain – Pipeline by Cara Therapeutics Inc, H2 2016 95

Neuropathic Pain – Pipeline by Catalyst Biosciences Inc, H2 2016 96

Neuropathic Pain – Pipeline by Cavion LLC, H2 2016 97

Neuropathic Pain – Pipeline by Centrexion Therapeutics Corp, H2 2016 98

Neuropathic Pain – Pipeline by Cerecor Inc, H2 2016 99

Neuropathic Pain – Pipeline by Chromocell Corp, H2 2016 100

Neuropathic Pain – Pipeline by Circuit Therapeutics Inc, H2 2016 101

Neuropathic Pain – Pipeline by CLL Pharma SA, H2 2016 102

Neuropathic Pain – Pipeline by Colby Pharmaceutical Company, H2 2016 103

Neuropathic Pain – Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 104

Neuropathic Pain – Pipeline by Crinetics Pharmaceuticals Inc, H2 2016 105

Neuropathic Pain – Pipeline by Cytogel Pharma LLC, H2 2016 106

Neuropathic Pain – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 107

Neuropathic Pain – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 108

Neuropathic Pain – Pipeline by Develco Pharma Schweiz AG, H2 2016 109

Neuropathic Pain – Pipeline by Dompe Farmaceutici SpA, H2 2016 110

Neuropathic Pain – Pipeline by Eisai Co Ltd, H2 2016 111

Neuropathic Pain – Pipeline by Eli Lilly and Company, H2 2016 112

Neuropathic Pain – Pipeline by Endece LLC, H2 2016 113

Neuropathic Pain – Pipeline by Evec Inc, H2 2016 114

Neuropathic Pain – Pipeline by Genecode AS, H2 2016 115

Neuropathic Pain – Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016 116

Neuropathic Pain – Pipeline by Glialogix Inc, H2 2016 117

Neuropathic Pain – Pipeline by Grunenthal GmbH, H2 2016 118

Neuropathic Pain – Pipeline by GW Pharmaceuticals Plc, H2 2016 119

Neuropathic Pain – Pipeline by Hydra Biosciences Inc, H2 2016 120

Neuropathic Pain – Pipeline by Immune Pharmaceuticals Inc, H2 2016 121

Neuropathic Pain – Pipeline by Inpellis Inc, H2 2016 122

Neuropathic Pain – Pipeline by Integral Molecular Inc, H2 2016 123

Neuropathic Pain – Pipeline by Intellipharmaceutics International Inc, H2 2016 124

Neuropathic Pain – Pipeline by iX Biopharma Ltd, H2 2016 125

Neuropathic Pain – Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 126

Neuropathic Pain – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 127

Neuropathic Pain – Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H2 2016 128

Neuropathic Pain – Pipeline by Johnson & Johnson, H2 2016 129

Neuropathic Pain – Pipeline by Kareus Therapeutics SA, H2 2016 130

Neuropathic Pain – Pipeline by Knopp Biosciences LLC, H2 2016 131

Neuropathic Pain – Pipeline by Kolon Life Science Inc, H2 2016 132

Neuropathic Pain – Pipeline by KPI Therapeutics Inc, H2 2016 133

Neuropathic Pain – Pipeline by Laboratorios Del Dr Esteve SA, H2 2016 134

Neuropathic Pain – Pipeline by Lexicon Pharmaceuticals Inc, H2 2016 135

Neuropathic Pain – Pipeline by Lohocla Research Corp, H2 2016 136

Neuropathic Pain – Pipeline by Lpath Inc, H2 2016 137

Neuropathic Pain – Pipeline by Mapi Pharma Ltd, H2 2016 138

Neuropathic Pain – Pipeline by Medestea Research & Production SpA, H2 2016 139

Neuropathic Pain – Pipeline by Medifron DBT Co Ltd, H2 2016 140

Neuropathic Pain – Pipeline by Medisyn Technologies Inc, H2 2016 141

Neuropathic Pain – Pipeline by Medy-Tox Inc, H2 2016 142

Neuropathic Pain – Pipeline by Merck & Co Inc, H2 2016 143

Neuropathic Pain – Pipeline by Nanomerics Ltd, H2 2016 144

Neuropathic Pain – Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 145

Neuropathic Pain – Pipeline by Neurocentrx Pharma Ltd, H2 2016 146

Neuropathic Pain – Pipeline by NeuroCycle Therapeutics GmbH, H2 2016 147

Neuropathic Pain – Pipeline by NeuroMax, H2 2016 148

Neuropathic Pain – Pipeline by NeurOp Inc, H2 2016 149

Neuropathic Pain – Pipeline by Newron Pharmaceuticals SpA, H2 2016 150

Neuropathic Pain – Pipeline by Nippon Chemiphar Co Ltd, H2 2016 151

Neuropathic Pain – Pipeline by NoNO Inc, H2 2016 152

Neuropathic Pain – Pipeline by Novaremed Ltd, H2 2016 153

Neuropathic Pain – Pipeline by Novartis AG, H2 2016 154

Neuropathic Pain – Pipeline by NsGene A/S, H2 2016 155

Neuropathic Pain – Pipeline by Omeros Corp, H2 2016 156

Neuropathic Pain – Pipeline by Orion Oyj, H2 2016 157

Neuropathic Pain – Pipeline by Patagonia Pharmaceuticals LLC, H2 2016 158

Neuropathic Pain – Pipeline by PeriphaGen Inc, H2 2016 159

Neuropathic Pain – Pipeline by Pfizer Inc, H2 2016 160

Neuropathic Pain – Pipeline by Pharmaleads SA, H2 2016 161

Neuropathic Pain – Pipeline by PharmEste Srl, H2 2016 162

Neuropathic Pain – Pipeline by Phosphagenics Ltd, H2 2016 163

Neuropathic Pain – Pipeline by Prismic Pharmaceuticals Inc, H2 2016 164

Neuropathic Pain – Pipeline by RaQualia Pharma Inc, H2 2016 165

Neuropathic Pain – Pipeline by Re-Pharm Ltd, H2 2016 166

Neuropathic Pain – Pipeline by Relmada Therapeutics Inc, H2 2016 167

Neuropathic Pain – Pipeline by Revance Therapeutics Inc, H2 2016 168

Neuropathic Pain – Pipeline by Saniona AB, H2 2016 169

Neuropathic Pain – Pipeline by Scilex Pharmaceuticals Inc, H2 2016 170

Neuropathic Pain – Pipeline by Shionogi & Co Ltd, H2 2016 171

Neuropathic Pain – Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016 172

Neuropathic Pain – Pipeline by Sphaera Pharma Pvt Ltd, H2 2016 173

Neuropathic Pain – Pipeline by Spherium Biomed SL, H2 2016 174

Neuropathic Pain – Pipeline by Sunovion Pharmaceuticals Inc, H2 2016 175

Neuropathic Pain – Pipeline by Syntrix Biosystems Inc, H2 2016 176

Neuropathic Pain – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 177

Neuropathic Pain – Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 178

Neuropathic Pain – Pipeline by Theranexus SAS, H2 2016 179

Neuropathic Pain – Pipeline by Theravasc Inc, H2 2016 180

Neuropathic Pain – Pipeline by Toray Industries Inc, H2 2016 181

Neuropathic Pain – Pipeline by Torrent Pharmaceuticals Ltd, H2 2016 182

Neuropathic Pain – Pipeline by Trevena Inc, H2 2016 183

Neuropathic Pain – Pipeline by Trigemina Inc, H2 2016 184

Neuropathic Pain – Pipeline by Virobay Inc, H2 2016 185

Neuropathic Pain – Pipeline by VistaGen Therapeutics Inc, H2 2016 186

Neuropathic Pain – Pipeline by Vitality Biopharma Inc, H2 2016 187

Neuropathic Pain – Pipeline by Yuhan Corp, H2 2016 188

Neuropathic Pain – Pipeline by Yungjin Pharm Co Ltd, H2 2016 189

Neuropathic Pain – Pipeline by Zynerba Pharmaceuticals Inc, H2 2016 190

Assessment by Monotherapy Products, H2 2016 191

Assessment by Combination Products, H2 2016 192

Number of Products by Stage and Target, H2 2016 194

Number of Products by Stage and Mechanism of Action, H2 2016 202

Number of Products by Stage and Route of Administration, H2 2016 211

Number of Products by Stage and Molecule Type, H2 2016 213

Neuropathic Pain – Dormant Projects, H2 2016 517

Neuropathic Pain – Dormant Projects (Contd..1), H2 2016 518

Neuropathic Pain – Dormant Projects (Contd..2), H2 2016 519

Neuropathic Pain – Dormant Projects (Contd..3), H2 2016 520

Neuropathic Pain – Dormant Projects (Contd..4), H2 2016 521

Neuropathic Pain – Dormant Projects (Contd..5), H2 2016 522

Neuropathic Pain – Dormant Projects (Contd..6), H2 2016 523

Neuropathic Pain – Dormant Projects (Contd..7), H2 2016 524

Neuropathic Pain – Dormant Projects (Contd..8), H2 2016 525

Neuropathic Pain – Dormant Projects (Contd..9), H2 2016 526

Neuropathic Pain – Dormant Projects (Contd..10), H2 2016 527

Neuropathic Pain – Dormant Projects (Contd..11), H2 2016 528

Neuropathic Pain – Dormant Projects (Contd..12), H2 2016 529

Neuropathic Pain – Dormant Projects (Contd..13), H2 2016 530

Neuropathic Pain – Dormant Projects (Contd..14), H2 2016 531

Neuropathic Pain – Dormant Projects (Contd..15), H2 2016 532

Neuropathic Pain – Dormant Projects (Contd..16), H2 2016 533

Neuropathic Pain – Dormant Projects (Contd..17), H2 2016 534

Neuropathic Pain – Dormant Projects (Contd..18), H2 2016 535

Neuropathic Pain – Dormant Projects (Contd..19), H2 2016 536

Neuropathic Pain – Dormant Projects (Contd..20), H2 2016 537

Neuropathic Pain – Dormant Projects (Contd..21), H2 2016 538

Neuropathic Pain – Dormant Projects (Contd..22), H2 2016 539

Neuropathic Pain – Dormant Projects (Contd..23), H2 2016 540

Neuropathic Pain – Dormant Projects (Contd..24), H2 2016 541

Neuropathic Pain – Discontinued Products, H2 2016 542

Neuropathic Pain – Discontinued Products (Contd..1), H2 2016 543

Neuropathic Pain – Discontinued Products (Contd..2), H2 2016 544

Neuropathic Pain – Discontinued Products (Contd..3), H2 2016 545

Neuropathic Pain – Discontinued Products (Contd..4), H2 2016 546

Neuropathic Pain – Discontinued Products (Contd..5), H2 2016 547

Neuropathic Pain – Discontinued Products (Contd..6), H2 2016 548

Neuropathic Pain – Discontinued Products (Contd..7), H2 2016 549

List of Figures

List of Figures

Number of Products under Development for Neuropathic Pain, H2 2016 36

Number of Products under Development for Neuropathic Pain – Comparative Analysis, H2 2016 37

Number of Products under Development by Companies, H2 2016 38

Number of Products under Investigation by Universities/Institutes, H2 2016 48

Comparative Analysis by Late Stage Development, H2 2016 50

Comparative Analysis by Clinical Stage Development, H2 2016 51

Comparative Analysis by Early Stage Products, H2 2016 52

Assessment by Monotherapy Products, H2 2016 191

Assessment by Combination Products, H2 2016 192

Number of Products by Top 10 Targets, H2 2016 193

Number of Products by Stage and Top 10 Targets, H2 2016 193

Number of Products by Top 10 Mechanism of Actions, H2 2016 201

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 201

Number of Products by Top 10 Routes of Administration, H2 2016 210

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 210

Number of Products by Top 10 Molecule Types, H2 2016 212

Number of Products by Stage and Top 10 Molecule Types, H2 2016 212

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports